0
RM0.00
  • An empty cart

    You have no item in your shopping cart

Blog Details

morf stock forecast
morf stock forecast

Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. Morphic’s stock was trading at $26.75 on January 1st, 2023. Since then, MORF shares have increased by 56.3% and is now trading at $41.82. In the past three months, Morphic insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,953,892.00 in company stock. While our free users beat the market by 7% per quarter, last quarter, our premium users have beaten the market by 22%.

  • The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.
  • In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
  • Users should not base their investment decision upon StockInvest.us.
  • The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.
  • MarketBeat has tracked 5 news articles for Morphic this week, compared to 2 articles on an average week.

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in Morphic Holding, Inc. . While the effectiveness of this highly sought-after metric is questiona… Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA. AIStockFinder is a company specialized in predictive algorithms.

The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat’s FREE daily newsletter.

The company’s average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. The highest analyst price target is $75.00 ,the lowest forecast is $56.00. The average price target represents 50.65% Increase from the current price of $41.82. MORF analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

MORF vs Biotech Stocks

At the moment the company generates 39M USD in revenues. Out of 6 analysts, 3 (50%) are recommending MORF as a Strong Buy, 3 (50%) are recommending MORF as a Buy, 0 (0%) are recommending MORF as a Hold, 0 (0%) are recommending MORF as a Sell, and 0 (0%) are recommending MORF as a Strong Sell. Stock can be purchased through just about any brokerage firm, including online brokerage services. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%.

An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. One share of MORF stock can currently be purchased for approximately $41.82.

morf stock forecast

If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan’s own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

The 8 analysts offering 1 year price forecasts for MORF have a max estimate of — and a min estimate of —. Morphic Holding, Inc. was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the … This stock has average movements during the day and with good trading volume, the risk is considered to be medium.

Is It Time to Buy? MORF Shares are down today.

You may use StockInvest.us and the contents contained in StockInvest.us solely for your own individual non-commercial and informational purposes only. Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. 83.47% during the next 3 months and, with a 90% probability hold a price between $76.73 and $94.34 at the end of this 3-month period. There may be delays, omissions, or inaccuracies in the Information. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

morf stock forecast

During the last day, the stock moved $2.50 between high and low, or 6.03%. For the last week, the stock has had daily average volatility of 5.93%. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.

Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference – Slideshow

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. The P/E ratio of Morphic is -26.30, which means are cannabis stocks the real deal, another gamestop or something else that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. A high percentage of insider ownership can be a sign of company health. Morphic has a short interest ratio (“days to cover”) of 7.9.

morf stock forecast

Morphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its “Creating knowledge” impact, which is false driven by its “Preclinical research services for physical health” and “Clinical research services for physiological diseases ” products. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Take the temperature and try it for free during one month. On its last earning announcement, the company reported a loss of -1.80$ per share.

Key Earnings Data

6 people have searched for MORF on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. MarketBeat has tracked 5 news articles for Morphic this week, compared to 2 articles on an average week.

Morphic Holding Stock Forecast for 2024

In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Any opinions, news, research, analyses, prices, or other information offered by AIStockFinder is provided as general market commentary, and does not constitute investment advice. AIStockFinder will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations … Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their https://day-trading.info/ stock ratings and see how they perform on a stock-by-stock basis. Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers. Morphic Holding has 50.65% upside potential, based on the analysts’ average price target. The highest, average, and lowest price target of all analysts.

Information is provided ‘as-is’ and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data. In 2027, MORF is forecast to generate $363,714,070 in revenue, with the lowest revenue forecast at $363,714,070 and the highest revenue forecast at $363,714,070. Forecst.com predicts future values using technical analysis of a large number of analytical parameters. MORF stock returns are also predicted based on historical data. Morphic Holding, Inc. delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022.

Morphic has only been the subject of 1 research reports in the past 90 days. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Each premium signal is sent to all our premium users by mail. They don’t need to monitor our website to act and trade optimally.

Leave your thought

Login

Lost your password?